Skip to main content

Table 1 Basic characteristics of the participants

From: The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials

Study Duration Inclusion criteria Participants (T/C) Age (years) Male (%) Outcome
T C T C
Jula 2015 12 weeks Dyslipidemia patients 120 (60/60) 48.4 ± 6.2 48.0 ± 6.2 100 100 Serum CoQ 10 concentrations
Oranje 2001 3 months Type 2 diabetes patients 19 (9/10) 64 ± 8 63 ± 8 100 70 Plasma CoQ 10 concentrations
Päivä 2005 8 weeks Dyslipidemia patients 48 (32/16) 31–69 31–69 N N Plasma CoQ 10 concentrations
Strey 2005 6 weeks Heart failure (NYHA II or III) with LVEF < 40% 48 (24/24) N N N N Plasma CoQ 10 concentrations
Mortensen 1997 6 weeks Dyslipidemia patients 45 (23/22) 52.9 (32,69) 54.8 (42,67) 60.9 40.9 Serum CoQ 10 concentrations
Morrison 2017 24 weeks Patients with HIV 147 (71/75) 45 (41,51) 47 (39,53) 81 76 Plasma CoQ 10 concentrations
McMurray 2010 3 months Heart failure (NYHA II or III) with LVEF < 40% 1103 (551/552) N N N N Serum CoQ 10 concentrations
Ghirlanda 1993 3 months Dyslipidemia patients 30 (20/10) 47 ± 8; 49 ± 10 47 ± 8 60; 50 70 Plasma CoQ 10 concentrations
Chitose 2014 6 months STEMI patients 75 (38/37) 64.1 ± 11.8 65.8 ± 12.4 73.7 75.7 Plasma CoQ 10 concentrations
Berthold 2006 14 days Healthy subjects 48 (24/24) 31.9 ± 8.8 28.6 ± 6.6 N N Plasma CoQ 10 concentrations
Barry 2001 4 weeks Healthy subjects 24 (12/12) 26 ± 5 26 ± 5 41.7 41.7 Plasma CoQ 10 concentrations
Ashton et al. 2011 26 weeks Heart failure (NYHA II or III) with LVEF < 40% 69 (32/37) N N N N Plasma CoQ 10 concentrations
  1. NYHA New York Heart Association, LVEF left ventricular ejection fraction, HIV human immunodeficiency virus, STEMI st segment elevation myocardial infarction, CAD coronary artery disease, CK creatine kinase, CoQ10 coenzyme Q 10, T treatment group, C control group, N not mentioned